OnDrugDelivery: BiologIC's view of the future for Drug Manufacturing

OnDrugDelivery: BiologIC's view of the future for Drug Manufacturing

BiologIC are hugely excited about Advanced Therapies (ATs) and see a new era of medicine enabled by these therapies.

One opportunity in this new era is the model of delivery of therapies to patients. BiologIC recently authored a thought leadership piece in OnDrugDelivery on how the current slow-moving blockbuster treatment model will make way for a fast-moving, patient-focused era of personalised medicine – creating new opportunities for flexible, decentralised AT manufacture closer to the patient.

Read the full text here:  https://www.ondrugdelivery.com/a-flexible-modular-platform-to-disrupt-the-blockbuster-manufacturing-model/

 We’d love to hear your thoughts and opinions on this, get in touch on This email address is being protected from spambots. You need JavaScript enabled to view it.

EnterpriseTECH 2019 – helping BiologIC drive the next wave of biological innovation

We recently had a very exciting meeting with our EnterpriseTECH team to explore the different commercialisation opportunities for our technology.

Getting a new business up and running is a busy time with many different things to do. It’s too easy to push forwards on unvalidated assumptions about where our technology could be applied. Our EnterpriseTECH team has undertaken market research to challenge these assumptions and taken a data driven approach to carry out a critical review of where our combination of digital biology and digital hardware will have the biggest impact.

We are excited to be supporting The Cambridge Judge Business School’s EnterpriseTECH 2019 scheme and have the next wave of entrepreneurs and business thinkers help shape the future of BiologIC.

BiologIC contributes to Phacilitate Automation Report 2019

Advanced Therapies (ATs) are a hugely exciting area of medicine although the very first regulatory cleared ATs have significant cost of goods. Decentralised manufacturing of these therapies – potentially at the point of need – is seen as a potential solution to the cost of goods issue amongst other challenges.

BiologIC recently contributed to the Phacilitate Automation report 2019 where we discuss decentralised manufacturing of ATs in the healthcare setting and the challenges of getting clinicians and the healthcare systems on-board with this.

In this piece we identify user needs for the decentralised manufacturing scenario and then consider what is required to realise the potential of decentralised manufacturing to address the current challenges in the AT sector.

We’d love to hear your thoughts and opinions on this, get in touch on This email address is being protected from spambots. You need JavaScript enabled to view it.